Loading clinical trials...
Loading clinical trials...
A Multicenter, Open-label, Single-dose Study to Evaluate Pharmacokinetics, Safety and Tolerability of Solifenacin Succinate Suspension in Pediatric Subjects From 5 to Less Than 18 Years of Age With Neurogenic Detrusor Overactivity (NDO)
Conditions
Interventions
Solifenacin succinate suspension 5 mg
Locations
7
Belgium
Site: 3201
Ghent, Belgium
Québec, Quebec, Canada
Site: 4501
Århus N, Denmark
Site: 3102
Utrecht, Netherlands
Site: 4801
Warsaw, Poland
Site: 90
Ankara, Turkey (Türkiye)
Start Date
March 13, 2012
Primary Completion Date
August 13, 2012
Completion Date
August 13, 2012
Last Updated
October 22, 2024
NCT06789406
NCT05362292
NCT07193407
NCT07195656
NCT07209397
NCT05799313
Lead Sponsor
Astellas Pharma Inc
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions